Figure 4
From: Targeting the NF-κB pathway enhances responsiveness of mammary tumors to JAK inhibitors
Ruxolitinib treatment increases nuclear localization of NF-κB in TAMs. BMDMs were treated with CM from HC11/R1 cells (a–c) and 4T1 cells (d–f) with ruxolitinib, and protein lysates from the cytoplasmic and nuclear fraction were immunoblotted for phospho-p65. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 Representative blots from n = 3 biological replicates.
